1. Philpott, April L, Fitzgerald, Paul B, Bailey, Neil W, Georgiou-Karistianis, Nellie, Cummins, Tarrant D R. 2016. A GABBR2 gene variant modifies pathophysiology in Huntington's disease. In Neuroscience letters, 620, 8-13. doi:10.1016/j.neulet.2016.03.038. https://pubmed.ncbi.nlm.nih.gov/27033668/
2. Al-Khfaji, Karrar Mahmood Shaker, Zamani, Nika Kooshki, Arefian, Ehsan. 2023. HSV-1 latency-associated transcript miR-H3 and miR-H4 target STXBP1 and GABBR2 genes. In Journal of neurovirology, 29, 669-677. doi:10.1007/s13365-023-01174-8. https://pubmed.ncbi.nlm.nih.gov/37668872/
3. D'Onofrio, Gianluca, Riva, Antonella, Di Rosa, Gabriella, Striano, Pasquale, Soler, Doriette. 2022. Paroxysmal limb dystonias associated with GABBR2 pathogenic variant: A case-based literature review. In Brain & development, 44, 469-473. doi:10.1016/j.braindev.2022.03.010. https://pubmed.ncbi.nlm.nih.gov/35414446/
4. Niu, Xiaomin, Liu, Fatao, Zhou, Yi, Chen, Zhiwei, Lu, Shun. 2017. Genome-wide DNA Methylation Analysis Reveals GABBR2 as a Novel Epigenetic Target for EGFR 19 Deletion Lung Adenocarcinoma with Induction Erlotinib Treatment. In Clinical cancer research : an official journal of the American Association for Cancer Research, 23, 5003-5014. doi:10.1158/1078-0432.CCR-16-2688. https://pubmed.ncbi.nlm.nih.gov/28490462/
5. Choi, Sujin, Lee, Soonchul, Han, Young-Hoon, Lee, Jusung, An, Hyun-Ju. 2022. miR-31-3p functions as a tumor suppressor by directly targeting GABBR2 in prostate cancer. In Frontiers in oncology, 12, 945057. doi:10.3389/fonc.2022.945057. https://pubmed.ncbi.nlm.nih.gov/36059697/
智鼠故事 
